Institutional and public market investors
Biotech Investor · 2 portfolio companies
Portfolio
2
Combined Value
$393.1M
Focus Areas
5
Top Stage
Phase 2
Investment Focus
Portfolio Companies
| Company | Valuation |
|---|---|
| Monopar Therapeutics | $368.9M |
| Vistagen Therapeutics | $24.1M |